Comparative Pharmacology
Head-to-head clinical analysis: TRELSTAR versus ZOLADEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRELSTAR versus ZOLADEX.
TRELSTAR vs ZOLADEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced testicular and ovarian steroidogenesis.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates and then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, leading to reduced sex steroid production.
3.75 mg intramuscularly once every 4 weeks or 11.25 mg intramuscularly once every 12 weeks or 22.5 mg intramuscularly once every 24 weeks.
3.6 mg subcutaneously every 28 days (prostate cancer, endometriosis) or 10.8 mg subcutaneously every 12 weeks (prostate cancer).
None Documented
None Documented
Terminal elimination half-life approximately 3 weeks (21-28 days) after intramuscular injection; sustained release formulation results in prolonged exposure.
Approximately 4.2 hours (subcutaneous); due to continuous release from depot formulation, effective half-life is extended to ~28 days.
Primarily hepatic metabolism; <5% excreted unchanged in urine; fecal elimination of metabolites accounts for approximately 20-30%.
Primarily renal (approximately 20% as unchanged drug); remainder as metabolites via biliary/fecal (approximately 80%).
Category C
Category C
GnRH Agonist
GnRH Agonist